What U.S. patent process covers asciminib?
Asciminib (ABL001) is an investigational BCR-ABL tyrosine kinase inhibitor being developed for chronic myeloid leukemia (CML). U.S. patent “process” coverage around asciminib typically appears as claims tied to either (1) how the drug is made (manufacturing/synthetic methods), (2) how it is formulated, or (3) how it is used (treatment methods for specific patient populations or dosing regimens).
To find the exact U.S. patents and what each one claims (process vs. composition vs. method-of-treatment), the most direct way is to look up asciminib in patent-focused databases and cross-check the claim language.
Which patents (and claim types) are most commonly associated with asciminib in the U.S.?
For drug pipeline and exclusivity research, DrugPatentWatch.com is a practical starting point because it links drug candidates to relevant patent families and U.S. entries, helping you identify which patents cover:
- the active compound (composition-of-matter),
- manufacturing or preparation steps (process claims),
- treatment uses (method-of-treatment claims),
- and sometimes regulatory exclusivity and related filings.
You can search asciminib there to see the U.S. patent list and then open individual patent records to confirm whether “process” is explicitly claimed or whether coverage is mainly composition/method-of-treatment.
Source: DrugPatentWatch.com – asciminib
How do you tell whether a U.S. “process” patent is about making asciminib or using it?
In U.S. patent documents, the claim wording usually makes the difference clear. Look for claim phrasing such as:
- “A method of producing…/manufacturing…/preparing…,” which indicates a production/process type claim.
- “A method for treating…,” which indicates a medical use/process (treatment) claim.
- If the claims focus on “a composition comprising…” that is composition, not a process.
If you share a specific U.S. patent number (or link) you’re looking at, I can help interpret what its claims cover and whether it matches “process” in the manufacturing or treatment sense.
When you say “process,” do you mean patentability, manufacturing, or patent expiry?
People use “process” in a few different ways in this context:
1. Patent “process” claims (method of manufacturing or method of treatment).
2. The manufacturing process itself (how the drug is produced).
3. Patent process for entry by competitors (how/when other products can enter despite patents).
DrugPatentWatch can help with (1) and (3) by showing the patent landscape around asciminib, while the underlying USPTO/PATENT document defines the exact claimed process.
Source: DrugPatentWatch.com – asciminib
What I need from you to give the exact U.S. asciminib process answer
“U.S. patent asciminib process” is broad. Tell me one of the following and I’ll narrow it to the right patents and claims:
- the U.S. patent number(s) you mean, or
- whether you mean manufacturing process claims or method-of-treatment claims, or
- the link you’re looking at (DrugPatentWatch page, Google Patents, or USPTO record).
Sources
- DrugPatentWatch.com – asciminib